Related Experiment Videos
Rosiglitazone
B H Wolffenbuttel1, J P Sels, M S Huijberts
1Dept. of Endocrinology & Metabolism, University Hospital Maastricht, P.O. Box 5800, NL-6202 AZ Maastricht, The Netherlands. bwo@sint.azm.nl
Expert Opinion on Pharmacotherapy
|May 5, 2001
Summary
Rosiglitazone, an insulin sensitizer, effectively lowers blood glucose in Type 2 diabetes patients. While generally safe, further research is needed on its long-term effects and combination therapy with insulin.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus involves impaired insulin secretion, reduced peripheral insulin action, and increased hepatic glucose production.
- Near-normal glucose control may mitigate microvascular and macrovascular complications in Type 2 diabetes.
- Thiazolidinediones, like rosiglitazone, enhance insulin sensitivity by activating the PPARgamma nuclear receptor.
Purpose of the Study:
- To evaluate the efficacy and safety of rosiglitazone in managing Type 2 diabetes mellitus.
- To assess rosiglitazone's impact on glycemic control in patients on various therapeutic regimens.
- To explore potential benefits beyond glycemic control and identify safety concerns.
Main Methods:
- Clinical studies involving Type 2 diabetic patients treated with diet, sulfonylurea, metformin, or insulin.
- Assessment of HbA1c levels as a primary efficacy endpoint.
- Monitoring for side effects, including hypoglycemia, gastrointestinal issues, fluid retention, and hepatotoxicity.
Main Results:
- Rosiglitazone effectively reduced HbA1c levels by 0.5-1.5% in diet-treated patients and 1.0-1.2% when added to sulfonylurea therapy.
- Preliminary data suggest glycemic improvement and a slight decrease in insulin dosage in insulin-treated patients.
- Rosiglitazone did not cause hypoglycemia or gastrointestinal side effects; fluid retention is a noted concern.
Conclusions:
- Rosiglitazone is an effective insulin sensitizer for Type 2 diabetes, offering moderate glycemic control improvements.
- Further investigation is required to determine the clinical relevance of potential benefits on blood pressure and microalbuminuria.
- Long-term studies are needed to assess beta-cell function preservation, diabetes-related complications, and atherosclerosis reduction, especially in combination with insulin therapy.